Benitec Biopharma Inc. Earnings Per Share Disclosure
Year Ended June 30, |
||||||||
2024 |
2023 |
|||||||
Net loss (US$’000) |
($ | 21,751 | ) | ($ | 19.562 | ) | ||
Deemed dividend |
(619 | ) | — | |||||
Net loss attributable to common stockholders |
($ | 22,370 | ) | ($ | 19,562 | ) | ||
Weighted average number of shares used in calculating basic and diluted earnings per share |
4,060,182 | 1,385,818 | ||||||
Basic and diluted loss per share |
($ | 5.51 | ) | ($ | 14.12 | ) | ||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.